文献速递抗栓抗凝管理药物不良反应与药物警戒

耐久性左心室辅助装置药物治疗综述

Pharmacotherapy for durable left ventricular assist devices.
PubMed 文献 · Pharmacotherapy · 2021-01-31

本文综述了耐久性连续流左心室辅助装置(LVAD)患者的药物治疗管理。作者检索2013年后MEDLINE数据库,优先纳入前瞻性随机对照研究,聚焦HeartMate II、HeartMate 3和HeartWare HVAD相关试验,系统总结LVAD药物治疗各主要领域的最佳实践。

要点

  • LVAD患者需联合用药以达最佳临床结局,2013年后多项多学科药物研究更新了认知。
  • 检索优先纳入前瞻性随机对照研究,其次为对照观察性研究、回顾性研究和病例系列。
  • 本文系统综述耐久性连续流LVAD患者最优药物管理的当前理解。

核心结论

  • 本文旨在全面综述耐久性连续流LVAD患者最优药物管理的当前理解。

研究设计与样本

  • 综述检索美国国家医学图书馆MEDLINE数据库,纳入2013年及以后发表的药物相关重要文献。
  • 纳入涉及HeartMate II、HeartMate 3和HeartWare HVAD的试验,优先选择前瞻性随机对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Left ventricular assist devices (LVADs) have revolutionized the care of patients with advanced heart failure, yet still require concomitant medications in order to achieve the best possible clinical outcomes. Since the outset of routine placement of durable, continuous-flow LVADs, much of the medication management of these patients to date has been based on International Society of Heart and Lung Transplantation (ISHLT) guidance, most recently published in 2013. Since 2013, numerous multidisciplinary pharmacotherapy publications have increased the LVAD community's understanding of best practices with respect to medications. We identified the major domains of LVAD medication management and conducted a comprehensive search of US National Library of Medicine MEDLINE® database using keywords chosen to identify medication-related publications of significance dated 2013 or later. Trials pertaining to the HeartMate II™ and the HeartMate™ 3 LVADs (Abbott, Chicago, IL) and the HeartWare™ HVAD™ System (Medtronic, Minneapolis, MN) were chosen for inclusion. Highest priority for inclusion was given to prospective, randomized, controlled studies. Absent these, controlled trials (retrospective or prospective observational) were given next-highest consideration, followed by retrospective uncontrolled studies, and finally case series. Reference lists of qualified publications were reviewed to find any other publications of interest that were not discovered on initial search. Case reports were generally excluded, except where the insight gained was deemed to be uniquely pertinent. This document serves to provide a comprehensive review of the current understanding of optimal medication management in patients with durable, continuous-flow LVADs.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Hollis IB, Doligalski CT, Jennings DJ, et al. Pharmacotherapy for durable left ventricular assist devices. Pharmacotherapy. 2021. PMID: 33278842. doi:10.1002/phar.2491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。